Favipiravir May be an Effective COVID-19 Treatment
November 25, 2020 09:00pm
By Sara Karlovitch, Assistant Editor
The co-occurrence of Clostridium difficile (C. difficile) and ulcerative colitis or Crohnâ€™s disease is associated with higher in-hospital mortality and greater health care costs and resource utilization, according to a recent study.
The co-occurrence of
and ulcerative colitis (UC) or Crohn’s disease (CD) is associated with higher in-hospital mortality and greater health care costs and resource utilization, according to a study from California researchers published in the
Clostridium difficile (C. difficile)European Journal of Gastroenterology & Hepatology
Considering mortality outcomes and health care costs are generally higher among patients with later disease diagnosis and co-occurring diseases, the findings from this study indicate the importance of early screening strategies for inflammatory bowel disease (IBD) or other gastrointestinal-related disorders in patients with
“IBD is a chronic inflammatory disease of the gastrointestinal tract that is associated with increased risks of infections as a result of both the disease process itself as well as the immunosuppressive therapies we use to treat the disease, [and] hospitalized patients with IBD are at particularly high risk of concurrent infectious complications, especially with
infection,” lead study author Robert Wong, MD, MS, of the Highland Hospital in Oakland, California, told
. “Our study demonstrates that infection with
among hospitalized IBD patients is associated with significantly increased risk of death and significantly increased risk of health care resource utilization.”
For the full article, visitMDmag.com.
C. difficileMD MagC. difficile